KRIYA.288

KRIYA.288 is an investigational gene therapy being developed by Kriya Therapeutics for the treatment of diabetes. The program was originally part of the pipeline at Terraza Pharma, which Kriya Therapeutics acquired in 2022. The therapy is designed to deliver genetic material directly to target cells to enable the durable, long-term expression of a therapeutic protein following a single administration. By leveraging viral vector-mediated gene transfer, KRIYA.288 aims to provide a one-time treatment option that maintains stable glycemic control, potentially reducing or eliminating the need for chronic daily medications or injections in patients with diabetes.